Skip to main content
SpringerLink
Log in

Clinical Implications of Soft Tissue Sarcomas

  • Chapter
  • First Online:
Imaging in Clinical Oncology

  • 2758 Accesses

Abstract

During recent years, the development of molecular biology has led to the integration of novel, targeted therapies into the treatment of sarcomas. Due to the ever-increasing number of new molecules, the combination of radiographic imaging and specific molecular techniques is a valuable tool in the decision-making process as to whether their development should be continued. Imaging is used for diagnostic purposes, assessment of response, and during follow-up. Special emphasis is given to the new type of so-called “response” not absolutely necessitating tumor shrinkage, driving to development of new response criteria. Functional imaging plays an essential role in these criteria especially in cases where rigorous evaluation is needed for changing therapeutic strategy. Finally, follow-up protocols are described.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 179.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Panicek DM, Gatsonis C, Rosenthal DI et al (1997) CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the Radiology Diagnostic Oncology Group. Radiology 202:237–246

    PubMed  CAS  Google Scholar 

  2. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2012). The ESMO/European Sarcoma Network Working Group. Annals of Oncology 23 (Supplement 7): vii92–vii99

    Google Scholar 

  3. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2012). The ESMO/European Sarcoma Network Working Group. Annals of Oncology 23 (Supplement 7): vii100–vii109

    Google Scholar 

  4. Crim JR, Seeger LL, Yao L et al (1992) Diagnosis of soft tissue masses with MR imaging: can benign masses be differentiated from malignant ones. Radiology 185:581–586

    PubMed  CAS  Google Scholar 

  5. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  PubMed  CAS  Google Scholar 

  6. Michaelis LC, Ratain MJ (2006) Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 6:409–414

    Article  PubMed  CAS  Google Scholar 

  7. Blanke C, Demetri G, von Mehren M et al (2008) Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT. J Clin Oncol 26(4):620–625

    Article  PubMed  CAS  Google Scholar 

  8. Dhani N, Tu D, Sargent DJ, Seymour L, et al (2009) Alternate endpoints for screening phase II studies. Clin Cancer Res 15:1873–1882

    Article  PubMed  CAS  Google Scholar 

  9. Van den Abbeele AD, Badawi RD (2002) Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GIST). Eur J Cancer 38:S60–S65

    Article  PubMed  Google Scholar 

  10. Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759

    Article  PubMed  Google Scholar 

  11. Prior J, Montemurro M, Orcurto MV et al (2008) Early Prediction of Response to Sunitinib After Imatinib Failure by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumor. J Clin Oncol 27:439–445

    Article  PubMed  Google Scholar 

  12. Stroobants S, Goeminne J, Seegers M et al (2003) 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39:2012–2020

    Article  PubMed  CAS  Google Scholar 

  13. Gayed I, Vu T, Iyer R et al (2004) The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45:17–21

    PubMed  CAS  Google Scholar 

  14. Desai J, Shankar S, Heinrich MC et al (2007) Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 13:5398–5405

    Article  PubMed  CAS  Google Scholar 

  15. Lassau N, Lamuraglia M, Chami L et al (2006) Gastro-intestinal stromal tumours treated with imatinib: monitoring response with contrast enhanced ultrasound. Am J Roentgenol 187:1267–1273

    Article  Google Scholar 

  16. Hayashida Y, Yakushiji T, Awai K et al (2006) Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: Initial results. Eur Radiol 16:2637–2643

    Article  PubMed  Google Scholar 

  17. Eilber F, Rosen G, Eckardt J et al (2001) Treatment-Induced Pathologic Necrosis: A Predictor of Local Recurrence and Survival in Patients Receiving Neoadjuvant Therapy for High-Grade Extremity Soft Tissue Sarcomas. J Clin Oncol 19:3203–3209

    PubMed  CAS  Google Scholar 

  18. Collin C, Godbold J, Hajdu S et al (1987) Localized extremity soft tissue sarcoma: an analysis of factors affecting survival. J Clin Oncol 5:601–612

    PubMed  CAS  Google Scholar 

  19. Gaynor JJ, Tan CC, Casper ES et al (1992) Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol 10:1317–1329

    PubMed  CAS  Google Scholar 

  20. Evilevitch V, Weber WA, Tap WD et al (2008) Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 14:715–720

    Article  PubMed  CAS  Google Scholar 

  21. Benz MR, Czernin J, Allen-Auerbach MS et al (2009) FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 15:2856–2863

    Article  PubMed  CAS  Google Scholar 

  22. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G et al (2010) Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. J Nucl Med 51:551–558

    Article  PubMed  Google Scholar 

  23. Tateishi U, Kawai A, Chuman H, et al (2011) PET/CT allows stratification of responders to neoadjuvant chemotherapy for high-grade sarcoma: a prospective study. Clin Nucl Med 36:526–532

    Article  PubMed  Google Scholar 

  24. Herrmann K, Benz M, Czernin J et al (2012) 18-FDG-PET/CT Imaging as an Early Survival Predictor in Patients with Primary High-Grade Soft Tissue Sarcomas Undergoing Neoadjuvant Therapy. Clin Cancer Res 18:2024–2031

    Article  PubMed  CAS  Google Scholar 

  25. Grosso F, Jones R, Demetri G et al (2007) Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 8:595–602

    Article  PubMed  CAS  Google Scholar 

  26. Casali PG, Messina A, Stacchiotti S et al (2004) Imatinib mesylate in chordoma. Cancer 101:2086–2097

    Article  PubMed  CAS  Google Scholar 

  27. Vanel D, Shapeero LG, De Baere T et al (1994) MR imaging in the follow up of malignant and aggressive soft tissue tumors: results of 511 examinations. Radiology 190:263–268

    PubMed  CAS  Google Scholar 

  28. Panicek D, Schwartz L (1999) MR imaging of bone marrow in patients with musculoskeletal tumors. Sarcoma 3:37–41

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bioclinic Oncology Unit, 86, Mitropoleos street, 54622, Thessaloniki, Greece

    Ioannis P. Boukovinas

Authors
  1. Ioannis P. Boukovinas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ioannis P. Boukovinas .

Editor information

Editors and Affiliations

  1. University of Athens, Greece, Athens, Greece

    Athanasios D. Gouliamos

  2. Hygeia and Mitera Hospital, Athens, Greece

    John Andreou

  3. Hygeia Hospital, Athens, Greece

    Paris Kosmidis

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Italia

About this chapter

Cite this chapter

Boukovinas, I.P. (2014). Clinical Implications of Soft Tissue Sarcomas . In: Gouliamos, A., Andreou, J., Kosmidis, P. (eds) Imaging in Clinical Oncology. Springer, Milano. https://doi.org/10.1007/978-88-470-5385-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-5385-4_12

  • Published:

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-5384-7

  • Online ISBN: 978-88-470-5385-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation